Sleep Disorders Trial, Recruiting NCT07723144 Sponsor: Medical University of Bialystok Condition: Sleep Disorders
Back to Sleep Disorders

Sleep Disorders Trial, Recruiting

NCT07723144
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with obstructive sleep apnea (OSA):

  • Adults between 18 and 65 years of age
  • People with moderate or severe sleep apnea, confirmed by an overnight sleep study showing 15 or more breathing interruptions per hour
  • People who are willing and able to sign a consent form agreeing to take part
  • People who are willing to have blood samples taken at multiple points during the study
  • People who are willing to use a breathing device (such as a CPAP machine) and accept being randomly assigned to start treatment either straight away or after a delay

For people joining as healthy comparison participants (controls):

  • Adults between 18 and 65 years of age
  • People with no sleep apnea, confirmed by an overnight sleep study showing fewer than 5 breathing interruptions per hour
  • People who are willing and able to sign a consent form agreeing to take part
  • People who are willing to have blood samples taken and complete study assessments

Who may not be able to join:

  • People with mild sleep apnea (between 5 and fewer than 15 breathing interruptions per hour on a sleep study)
  • People whose breathing interruptions during sleep originate from the brain rather than a physical airway blockage (known as central sleep apnea)
  • People who have received treatment for sleep apnea in the past 3 months
  • People with a body mass index (BMI) of 40 or above (a measure of body weight relative to height)
  • People with serious heart or blood vessel disease
  • People with serious kidney disease or significantly reduced kidney function
  • People with significant liver disease
  • People with ongoing conditions affecting the immune system, such as autoimmune or rheumatic diseases, or other long-term inflammatory conditions
  • People with active cancer or any other condition known to cause widespread inflammation in the body
  • People with long-term lung or breathing conditions, such as asthma or chronic obstructive pulmonary disease (COPD)
  • People who have had a respiratory infection (such as a cold or chest infection) within the 4 weeks before enrolling
  • People who have had major surgery or a significant injury within the past 3 months
  • People with a long-term condition causing blocked or inflamed sinuses (chronic rhinosinusitis)
  • People currently taking steroid tablets, medicines that suppress the immune system, chemotherapy-type drugs, long-term anti-inflammatory medications, or other medicines that may affect inflammation markers in the blood
  • People who are pregnant, or who have any other condition that the trial doctors consider would make participation unsafe or affect the study results (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +48 85 831 82 69

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Medical University of Bialystok
Registry
ClinicalTrials.gov
Start date
19 December 2025
Est. completion
19 June 2029

Where this trial is recruiting

🇵🇱 Poland

Primary endpoints

Difference in blood biomarker concentrations between participants with obstructive sleep apnea (OSA) and non-OSA controls at baseline; Change in blood biomarker concentrations in OSA participants after positive airway pressure (PAP) therapy.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov